V-DOS 47

Drug Profile

V-DOS 47

Alternative Names: V-DOS-47

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helix BioPharma
  • Developer Helix BioPharma; Helix Polska; National Research Council Canada
  • Class Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Vascular endothelial growth factor receptor-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer
  • Research Cancer

Most Recent Events

  • 01 Sep 2017 Helix Biopharma has patent protection for DOS47 technology (Helix BioPharma pipeline, August 2017)
  • 16 Mar 2017 Preclinical trials in Breast cancer in Poland (unspecified route)
  • 19 Jul 2016 Early research in Cancer in Canada (unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top